Zobrazeno 1 - 5
of 5
pro vyhledávání: '"María del Carmen Álamo de la Gala"'
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
The development of immune checkpoint inhibitors has revolutionized the landscape of treatment of advanced melanoma in recent years. Based on the efficacy results of the phase III CheckMate 067 trial, nivolumab in combination with ipilimumab is one of
Externí odkaz:
https://doaj.org/article/420f01958705471bbfd0c7f1fc9d8bd7
Autor:
Lourdes Sevilla-Ortega, Lara Ferrándiz-Pulido, Natalia Palazón-Carrión, María del Carmen Álamo de la Gala, Rubén de Toro-Salas, José Garnacho-Montero, José Antonio Marcos-Rodríguez, Ana Agudo Martínez, Omar Araji-Tiliani, María Cinta Calvo-Morón, José Miguel Barquero-Aroca, Antonio Ramón Fernández-López, José María Jaime-Borrego, Juan Carlos Santos-Jiménez, David Moreno-Ramírez, Luis de la Cruz-Merino
Publikováno v:
Cancers, Vol 13, Iss 21, p 5485 (2021)
Background. Isolated limb perfusion (ILP) is a locoregional procedure indicated by the unresectable melanoma of the limbs. Its complexity and highly demanding multidisciplinary approach means that it is a technique only implemented in a few referral
Externí odkaz:
https://doaj.org/article/4e330b5c99654faaa261eba27e256008
Autor:
Iván Márquez-Rodas, Caroline Dutriaux, Philippe Saiag, Luis de la Cruz Merino, Eduardo Castanon Álvarez, Caroline Robert, Juan F. Rodríguez-Moreno, Ana M. Arance, Pablo Cerezuela-Fuentes, Henry Montaudié, Miguel F. Sanmamed, María González Cao, Julie Charles, María Pilar López Criado, Alfonso Berrocal, Enrique de Miguel, Elisa Funk-Brentano, Sorilla Prey, María del Carmen Álamo de la Gala, Javier Sánchez López, Helena Escuin-Ordinas, Sonia Macia, Marisol Quintero, Marya F. Chaney, Stéphane Dalle
Publikováno v:
Cancer Research. 82:CT014-CT014
Background: BO-112 is a double stranded synthetic RNA formulated with polyethyleneimine that mimics a viral infection. Through dendritic cells activation, increase in CD8 T-cell infiltration and interferons induction, it produces an immunogenic cell
Autor:
Ruth Roman, Philippe Saiag, Caroline Dutriaux, Luis de la Cruz Merino, Eduardo Castanon, Miguel F. Sanmamed, Caroline Robert, Juan F. Rodríguez-Moreno, Pablo Cerezuela-Fuentes, Ana M. Arance, María González Cao, Henry Montaudié, María Pilar López Criado, Julie Charles, Alfonso Berrocal, María del Carmen Álamo de la Gala, Enrique de Miguel, Elisa Funk-Brentano, Sorilla Prey, Eva Muñoz-Couselo, Delvys Rodríguez Abreu, Juan Martín-Liberal, Helena Escuin-Ordinas, Mark Branum, Sonia Macia, Marisol Quintero, Javier Sánchez López, Marya F. Chaney, Beatriz García-Peláez, Marta Vives-Usano, Miguel Ángel Molina, Stéphane Dalle, Iván Márquez-Rodas
Publikováno v:
Cancer Research. 82:CT107-CT107
Background: There is a lack of predictive biomarkers for immunotherapy in melanoma. In terms of IHC, there is no strong rational to support the use of PD-L1 expression. BRAF mutations occur in 40-50% of melanomas and the MAPK pathway may also be acti
Autor:
Francisco Javier García-Gómez, María Del Carmen Álamo-de-la-Gala, Ignacio León-Asuero-Moreno, Juan J. Ríos-Martín, María Cinta Calvo-Morón
Publikováno v:
Clinical Nuclear Medicine. 45:1005-1006
The thyroid gland is an uncommon location for metastasis. We report a 59-year-old woman with a history of cutaneous malignant melanoma. A unique hypermetabolic mass on the left thyroid lobe was identified by control F-FDG PET/CT scan, leading to dysp